NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note issued to investors on Monday. The brokerage issued a hold rating on the stock.

Separately, Ascendiant Capital Markets reduced their price target on NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a research report on Monday, November 11th.

NovaBay Pharmaceuticals Price Performance

Shares of NYSE:NBY opened at $0.62 on Monday. The company’s 50-day moving average price is $0.67 and its two-hundred day moving average price is $1.49. NovaBay Pharmaceuticals has a one year low of $0.36 and a one year high of $11.45. The stock has a market capitalization of $3.05 million, a PE ratio of -0.01 and a beta of 0.73.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.